Contrast-induced Nephropathy Clinical Trial
Official title:
Red Blood Cell Distribution Width as a Predictor Marker of Contrast Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention
Contrast Induced Nephropathy is an acute renal insufficiency defined as a 25% or 0.5 mg/dl increase over the baseline of the serum creatinine level 24 h to 72 h after intravascular administration of a contrast agent.
Contrast Induced Nephropathy has been introduced an important complication after coronary
angiography and Percutaneous Coronary Intervention .
The development of Contrast Induced Nephropathy after Percutaneous Coronary Intervention is
associated with poor clinical outcomes including prolonged hospitalization, increased costs,
increased rates of end-stage renal failure, myocardial infarction, repeat revascularization,
and short- and long-term mortality.
Contrast Induced Nephropathy follows decreased renal perfusion and administration of
nephrotoxic medications as the third most common cause of renal insufficiency during
hospitalization.
Patients with acute coronary syndrome have a 3-fold higher risk of developing Contrast
Induced Nephropathy .Therefore ,predicting contrast nephropathy and initiating therapeutic
preventive strategies are very important.
Red Blood Cell Distribution Width is a quantitive marker of the variability on size of
erythrocyte.
It is a routine assay of Complete Blood Count that doesn't require an additional cost, that
is calculated by dividing the standard deviation of the mean cell size by the Mean
Corpuscular Volume of the red cells and multiplying by 100 to convert to a percentage.
Normal range of Red Blood Cell Distribution Width 11-16%. Increased Red Blood Cell
Distribution Width means increased variability in red blood cell size owing to ineffective
erythrocyte production, which is associated with indices of inflammation and
pro-inflammatory cytokines such as interleukin-6 .
On the other hand, suggested mechanisms underlying Contrast Induced Nephropathy include
cytotoxic effects, factors that affect renal hemodynamic, and regional hypoxia.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
| Recruiting |
NCT02088502 -
Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy
|
Phase 2/Phase 3 | |
| Completed |
NCT03329443 -
The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
|
Phase 2 | |
| Recruiting |
NCT04864847 -
Clinical Validation of the RENISCHEM L-FABP POC Assay
|
||
| Completed |
NCT03627130 -
The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
|
Phase 2 | |
| Active, not recruiting |
NCT03736018 -
Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients
|
N/A | |
| Withdrawn |
NCT04603261 -
Time to Excretion of Contrast, a Maastricht Prospective Observational Study
|
||
| Withdrawn |
NCT04598516 -
Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
|
||
| Recruiting |
NCT03755700 -
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
|
Phase 3 | |
| Active, not recruiting |
NCT04606056 -
Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans
|
||
| Terminated |
NCT02440646 -
Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
|
||
| Completed |
NCT00175227 -
Prevention of Contrast-Induced Nephropathy
|
N/A | |
| Completed |
NCT04014153 -
CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?
|
||
| Withdrawn |
NCT04597892 -
Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast
|
||
| Completed |
NCT03305874 -
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
|
||
| Not yet recruiting |
NCT01871792 -
Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction
|
Phase 4 | |
| Not yet recruiting |
NCT06429345 -
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
|
Phase 4 | |
| Recruiting |
NCT05271448 -
Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography
|
N/A | |
| Withdrawn |
NCT03806725 -
Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
|
||
| Completed |
NCT04163250 -
Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary Angiography
|